Nearly 20 States Scale Back HIV Medication Programs

Follow Drugslib on

By HealthDay Staff HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 3, 2026.

via HealthDay

TUESDAY, March, 3, 2026 — A growing number of states are rolling back financial help for HIV medications.

An analysis released March 2 by the health research group KFF found that 18 states have adopted cost-cutting changes to their AIDS Drug Assistance Programs, known as ADAPs.

Five more states are considering similar steps.

ADAP programs are funded through the federal Ryan White Federal HIV Program. They help pay for HIV medications, provide drugs at no cost to some patients and cover insurance premiums for others.

When taken daily, the medications suppress the virus to undetectable levels, which means a person cannot pass HIV to others.

Experts warn that stopping this treatment can increase new infections and cause the virus to become resistant to medication.

The largest change took effect over the weekend in Florida. The state ended benefits for at least 16,000 residents living with HIV and stopped covering Biktarvy, the most widely prescribed HIV medication.

Florida’s ADAP program serves more than 32,000 clients, making it the nation’s largest.

In January, the state lowered income eligibility from 400% of the federal poverty level to 130%. That means an individual must now earn no more than $20,748 per year to qualify. The previous limit was $63,840.

The Florida Department of Health cited a projected $120 million budget shortfall but has not released any more information.

But the change is already causing fear in patients.

“We’re seeing patients across the state full of anxiety and fear rationing their lifesaving medication,” Esteban Wood, director of advocacy and legislative affairs at the AIDS Healthcare Foundation, told The New York Times.

“These are people who have no other safety net,” he added. “ADAP is the safety net.”

The foundation has filed a legal injunction to block Florida’s restrictions.

To help residents who lose premium support, the Centers for Medicare & Medicaid Services opened a special enrollment period for Floridians. Those affected can choose a new health plan through April 30.

ADAP programs support about 25% of the 1.2 million people living with HIV in the United States.

Enrollment increased by 30% from 2022 to 2024, in part because states began removing people from Medicaid after the pandemic.

At the same time, federal funding has remained flat for more than a decade, even as drug prices and insurance premiums have increased.

“Effectively, programs are being asked to do more with less federal funding,” Lindsey Dawson, associate director of HIV policy at KFF, told The Times.

Other states have reduced income eligibility limits or cut back on the number of medications they cover.

Pennsylvania, for example, lowered its eligibility criteria for income from 500% of the federal poverty level to 350%.

Experts warn that more states may follow, especially as work requirements push some folks off Medicaid.

“We’re expecting to see more states anticipating or contending with budget deficits, and we do anticipate a growing number of states having to implement cost-containment measures," Tim Horn, director of medication access at the National Alliance of State and Territorial AIDS Directors, told The Times.

Wood of the AIDS Healthcare Foundation summed up the situation succinctly.

“This is really an economic disaster, a public health disaster, a moral disaster,” he said.

Sources

  • The New York Times, March 2, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-03-04 01:42

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords